4-methoxy-N-[4-[[4-(1,3-thiazol-2-ylsulfamoyl)anilino]methyl]phenyl]benzamide | 1369424-22-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methoxy-N-[4-[[4-(1,3-thiazol-2-ylsulfamoyl)anilino]methyl]phenyl]benzamide
• CAS: 1369424-22-5
• 化学式: C₂₄H₂₂N₄O₄S₂
• 分子量: 494.595
• InChiKey: WKSCRKUUGNMFTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  磺胺噻唑 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 反应 15.5h， 生成 4-methoxy-N-[4-[[4-(1,3-thiazol-2-ylsulfamoyl)anilino]methyl]phenyl]benzamide
  参考文献：
  名称：

  Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors

  摘要：

  Fifteen novel sulfathiazole-related compounds were designed as PTP1B inhibitors based on a previously reported allosteric inhibitor (1) of PTP1B. These compounds were synthesized and evaluated against human recombinant PTP1B. Six compounds (3, 4, 8 and 14-16) exhibited significant inhibitory activity against PTP1B. The most active compound (16) showed IC50 value of 3.2 mu M and kinetic analysis indicated that it is a non-competitive inhibitor of PTP1B. Furthermore, compound 16 demonstrated excellent selectivity to PTP1B over other PTPs. It also displayed in vivo insulin sensitizing effect in the insulin resistant mice. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.073

文献信息

• 芳酮和芳酰胺类化合物及其制法和药物用途
  申请人：中国医学科学院药物研究所

  公开号：CN102382076B

  公开（公告）日：2016-08-17

  本发明公开了式I化合物所示新的芳酮和芳酰胺类化合物，其顺反异构体及生理上可接受的盐，溶剂化物以及结晶形式，所述化合物的制备方法，含有所述化合物的药物制剂，以及所述化合物在治疗与蛋白酪氨酸磷酸酯1B相关疾病的临床中的应用。
• Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors
  作者：Yan-Bo Tang、Dianyun Lu、Zheng Chen、Chun Hu、Ying Yang、Jin-Ying Tian、Fei Ye、Li Wu、Zhong-Yin Zhang、Zhiyan Xiao

  DOI：10.1016/j.bmcl.2013.02.073

  日期：2013.4

  Fifteen novel sulfathiazole-related compounds were designed as PTP1B inhibitors based on a previously reported allosteric inhibitor (1) of PTP1B. These compounds were synthesized and evaluated against human recombinant PTP1B. Six compounds (3, 4, 8 and 14-16) exhibited significant inhibitory activity against PTP1B. The most active compound (16) showed IC50 value of 3.2 mu M and kinetic analysis indicated that it is a non-competitive inhibitor of PTP1B. Furthermore, compound 16 demonstrated excellent selectivity to PTP1B over other PTPs. It also displayed in vivo insulin sensitizing effect in the insulin resistant mice. (C) 2013 Elsevier Ltd. All rights reserved.